Midostaurin Patent Expiration
Midostaurin is used for treating aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, mast cell leukemia, and newly diagnosed acute myeloid leukemia with FLT3 mutation-positive. It was first introduced by Novartis Pharmaceuticals Corp
Midostaurin Patents
Given below is the list of patents protecting Midostaurin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rydapt | US8575146 | Pharmaceutical uses of staurosporine derivatives | Dec 02, 2030 | Novartis |
| Rydapt | US7973031 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity | Oct 09, 2028 | Novartis |
| Rydapt | US8222244 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct 29, 2022
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Midostaurin's patents.
Latest Legal Activities on Midostaurin's Patents
Given below is the list recent legal activities going on the following patents of Midostaurin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Court Processing Terminated | 03 Apr, 2024 | US7973031 |
| Maintenance Fee Reminder Mailed Critical
| 04 Mar, 2024 | US8222244 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Dec, 2022 | US7973031 |
| Patent Term Extension Certificate Critical
| 27 Apr, 2022 | US7973031 |
| Withdrawal of Application for PTE Critical
| 10 Mar, 2022 | US8222244 |
| Notice of Final Determination -Eligible | 10 Mar, 2022 | US7973031 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Apr, 2021 | US8575146 |
| 37 CFR 1.750 Request for reconsideration | 15 Apr, 2021 | US7973031 |
| Notice of Final Determination -Election Required | 18 Mar, 2021 | US7973031 |
| Notice of Final Determination -Election Required | 18 Mar, 2021 | US8222244 |
Midostaurin's Family Patents
